Compass Therapeutics, Inc. CMPX NASDAQ

Compass Therapeutics, Inc. (CMPX) reported total assets of $219.59M and total liabilities of $22.8M for fiscal year 2025, resulting in total equity of $196.79M.

The company held $208.91M in cash and short-term investments. Total debt stood at $9.83M, with net debt of $-20.81M. The Debt-to-Equity (D/E) ratio was 0.05 (conservative).

Current ratio is 15.02, indicating strong short-term liquidity.

Criteria supported by this page:

• HEALTH (100/100, Pass) — Debt-to-Equity of 0.05, current ratio of 15.02 — balance sheet is strong
• MOAT (52/100) — Total assets $219.59M and equity $196.79M support the company's competitive scale
• VALUE (100/100) — Debt-to-Equity 0.05 contributes to the overall valuation risk assessment

Overall SharesGrow Score: 59/100 with 3/7 criteria passed.

NAMS

NewAmsterdam Pharma Company N.V.

$34.44

-4.99%

GPCR

Structure Therapeutics Inc.

$53.19

-1.95%

IDYA

IDEAYA Biosciences, Inc.

$32.35

-1.43%

ELVN

Enliven Therapeutics, Inc.

$44.85

+2.33%

ANAB

AnaptysBio, Inc.

$70.22

+2.17%

TYRA

Tyra Biosciences, Inc.

$35.27

-0.98%

MLTX

MoonLake Immunotherapeutics

$18.78

+1.90%

GLUE

Monte Rosa Therapeutics, Inc.

$17.50

-0.28%